Table 1.

Patient demographics and clinicopathologic data overall and by promoter hypermethylation status on pretreatment saliva by using the full panel

CharacteristicsOverall, n (%)Full panel salivaP
Unmethylated, n (%)Methylated, n (%)
Age
 <60 years36 (59.0)17 (60.7)19 (57.6)0.804
 ≥60 years25 (40.1)11 (39.3)14 (42.4)
Race
 Caucasian45 (73.8)19 (67.9)26 (78.8)
 African-American13 (21.3)9 (32.1)4 (12.1)0.060
 Other3 (4.9)0 (0)3 (9.1)
Gender
 Male50 (82.0)25 (89.3)25 (75.8)0.171
 Female11 (18.0)3 (10.7)8 (24.2)
Alcohol consumption
 No14 (27.5)7 (28.0)7 (26.9)1.000
 Yes37 (72.5)18 (72.0)19 (73.1)
Tobacco consumption
 No9 (15.3)4 (14.8)5 (15.6)1.000
 Yes50 (84.7)23 (85.2)27 (84.4)
Tumor site
 Oral cavity30 (49.2)11 (39.3)19 (57.6)
 Oropharynx19 (31.1)9 (32.1)10 (30.3)0.209
 Larynx/hypopharynx12 (19.7)8 (28.6)4 (12.1)
HPV
 Negative43 (70.5)19 (67.9)24 (72.7)0.678
 Positive18 (29.5)9 (32.1)9 (27.3)
pT stage
 pT1/T233 (55.0)18 (64.3)15 (46.9)0.176
 pT3/T427 (45.0)10 (35.7)17 (53.1)
pN stage
 pN026 (44.8)13 (46.4)13 (43.3)0.813
 pN+32 (55.2)15 (53.6)17 (56.7)
Extracapsular spread
 No36 (64.3)18 (64.3)18 (64.3)1.000
 Yes20 (35.7)10 (35.7)10 (35.7)
Margins
 Negative34 (66.7)18 (69.2)16 (64.0)0.692
 Positive17 (33.3)8 (30.8)9 (36.0)
Lymphvascular invasion
 No40 (78.4)21 (91.3)19 (67.9)0.084
 Yes11 (21.6)2 (8.7)9 (32.1)
Perineural invasion
 No43 (87.8)21 (91.3)22 (84.6)0.671
 Yes6 (12.2)2 (8.7)4 (15.4)